BCR: a new target in resistance mediated by BCR/ABL-315I?

Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the “gatekeeper” mutation T315I confers resistance against all approved TKIs, with the only exception of ponatinib, a multi-targeted kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Gerhart Oliver, Ruthardt, Martin, Mian, Afsar Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773704/
https://www.ncbi.nlm.nih.gov/pubmed/27014420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773704/
https://www.ncbi.nlm.nih.gov/pubmed/27014420

Ejemplares similares